J. Ross Maclean, MD

home / authors / j-ross-maclean-md

Articles

January 20th 2015

Value-Based Insurance Design: Benefits Beyond Cost and Utilization

Teresa B. Gibson, PhD J. Ross Maclean, MD Michael E. Chernew, PhD A. Mark Fendrick, MD Colin Baigel, MBChB

The authors provide a framework to capture additional benefits that may result from VBID programs, extending beyond utilization and outcomes to productivity, engagement, and talent.

November 30th 2012

Coverage and Use of Cancer Therapies in the Treatment of Chronic Myeloid Leukemia

Theodore Darkow, PharmD J. Ross Maclean, MD Geoffrey F. Joyce, PhD Dana Goldman, PhD Darius N. Lakdawalla, PhD

November 30th 2012

Value of Survival Gains in Chronic Myeloid Leukemia

Wesley Yin, PhD John R. Penrod, PhD J. Ross Maclean, MD Darius N. Lakdawalla, PhD Tomas Philipson, PhD

Although clinical trial data have quantified patient survival gains associated with tyrosine kinase inhibitors in chronic myeloid leukemia, the overall value of these benefits is unknown.

November 1st 2004

A Randomized Study to Decrease the Use of Potentially Inappropriate Medications Among Community-dwelling Older Adults in a Southeastern Managed Care Organization

Donna M. Fick, PhD, RN J. Ross Maclean, MD Nancy A. Rodriguez, RN Louise Short, MD, MSc Richard Vanden Heuvel, MPA Jennifer L. Waller, PhD Rebecca L. Rogers, PhD

February 1st 2002

Comparison of Two Systems for Clinical Practice Profiling in Diabetic Care: Medical Records Versus Claims and Administrative Data

J. Ross Maclean, MD Donna M. Fick, RN, PhD Wayne K. Hoffman, MD Coleman T. King, MD Eric R. Lough, MD Jennifer L. Waller, PhD